Axsome Therapeutics, Inc. to Present Data Spanning the Symbravo® (Meloxicam and Rizatriptan) Clinical Program At the 67Th Annual Scientific Meeting of the American Headache Society

Published: 2025-06-18 10:05:58 ET AXSM

Published on 06/18/2025 at 10:05

Axsome Therapeutics, Inc. announced that data from across the SYMBRAVO (meloxicam and rizatriptan) clinical program will be presented at the 67th Annual Scientific Meeting of the American Headache Society (AHS), being held June 19-22, 2025, in Minneapolis, Minnesota. Details for the presentations are as follows: Title: Efficacy of SYMBRAVO® (MoSEIC? meloxicam and rizatriptan) by Baseline Migraine-Associated Disability: Post-Hoc Analysis of the INTERCEPT Trial.

Lead Author: Stewart Tepper, MD, Clinical Professor of Neurology at the Geisel School of Medicine at Dartmouth and Vice President of the New England Institute for Neurology and Headache. Presentation Date and Time: Thursday, June 19, 6 - 7:30 p.m. Central Time. Poster Number: P-316.

Title: Long-Term Effects of SYMBRAVO® (MoSEIC? meloxicam and rizatriptan) on Headache Burden and Quality of Life: Results of the MOVEMENT Trial. Lead Author: Richard B. Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine.

Presentation Date and Time: Thursday, June 19, 6 - 7:30 p.m. Central Time. Poster Number: P-330. Title: Efficacy and Safety of SYMBRAVO® (MoSEIC?

meloxicam and rizatriptan) in Participants with Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results from the EMERGE Trial. Lead Author: Richard B. Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine. Presentation Date and Time: Saturday, June 21, 8:50 - 9 a.m. Central Time.

Session: Industry Abstracts IOR-03.